A CD28/CD40 based chimeric costimulatory antigen receptor (CoStAR™) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes Post date June 27, 2023 ← Anti-folate Receptor Alpha (FRα) CoStimulatory Antigen Receptor (CoStAR™) Improves T-cell Function Across Physiologically Relevant Ranges of FRα Expression and T-cell Receptor Affinities → Single cell RNA sequencing reveals functionally validated signatures of cytotoxicity in anti-FRá CoStimulatory Antigen Receptor (CoStAR™) activated CD4+ T cells.
Instil BioInstil Bio